Bon Natural Life

Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.

Tenon Medical, a biotech firm specializing in enhancing surgical solutions for the SI joint, was established in 2012 in Morgan Hill, California.

Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions.

CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also develops and commercializes tissue repair products for orthobiologics. The company's products are based on the rhCollagen that is produced with CollPlant’s proprietary plant-based genetic engineering technology. The rhCollagen BioInk is ideal for 3D bioprinting of tissues and organs, and the unique Vergenix line of rhCollagen products contains a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote rapid optimal healing of acute and chronic wounds. CollPlant is headquartered in Rehovot, Israel.

iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early detection and prediction of pregnancy complications, particularly preeclampsia.

Aptevo Therapeutics is a biotech company based in Seattle that focuses on developing new treatments for cancer and blood disorders. They use a special technology called ADAPTIR™ to improve outcomes for cancer patients. The company is known for its supportive work environment, culture of innovation, and unique platform technology. As a result, Aptevo has been able to attract talented individuals with experience in other leading biotech companies such as Trubion, ZymoGenetics, Immunex, Dendreon, and VLST.

Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic cancer. Oblique Therapeutics is an early stage innovation-driven pharmaceutical company aiming at developing transformative medicines against advanced and metastatic cancer.

Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.

Flare Therapeutics is a biotech firm that is venturing into a new therapeutic domain by taking a unique approach to decode the biology of transcription factors, in order to develop remedies in the form of small molecule medications. The team at Flare has discovered certain areas known as 'switch sites', which can be targeted for governing transcription factors and correcting mutation-induced ailments. Through its drug discovery program, which primarily centers around precision oncology, Flare has made significant progress in developing a drug pipeline aimed at tackling well-established transcription factors, and is looking to expand into fields such as neurology, immunology and inflammation, as well as rare genetic disorders.

Pictor is an in-vitro diagnostics company that offers a patented multiplexed platform for highly accurate and efficient testing of complex and infectious diseases for human and animal health. PictArray™ multiplexed technology makes it possible to test multiple disease markers in a single test simultaneously – with higher sensitivity, faster throughput, and reduced turn-around time. The company’s lead product, PictArray™ SARS-CoV-2 IgG ELISA Kit, enables more informed clinical intervention to reduce the threat of COVID-19

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an oral therapeutic designed to be a superior and safer Vitamin K antagonist (VKA) anticoagulant for patients with implanted cardiac devices or rare cardiovascular (CV) conditions. Cadrenal strives to improve outcomes and reduce adverse events for these patients such as strokes, heart attacks, bleeds, and deaths. These patients also lack approved chronic anticoagulation options besides warfarin, well-known for its serious side effects and frequent drug-drug interactions, resulting in complicated treatment management. Cadrenal’s drug candidate, tecarfarin, is a new VKA anticoagulant with extensive clinical data showing it is potentially superior and safer than warfarin, resulting in fewer adverse events. Tecarfarin is metabolized via a different pathway than warfarin and data demonstrate that its efficacy is unaffected by common drug-drug interactions or kidney impairment, which are common in these patients. Phase 2/3 clinical trials show that tecarfarin may offer more stability and time in therapeutic range (TTR) that inversely correlates with major events. Tecarfarin received an orphan drug designation for advanced heart failure patients with left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease (ESKD) patients with atrial fibrillation. Cadrenal is opportunistically pursuing pivotal clinical trials with LVAD patients along with clinical and commercial partnership opportunities to advance tecarfarin. The company’s plans also include studying patients with mechanical heart valves who experience anticoagulation difficulties because of genetic warfarin resistance, polypharmacy, or kidney impairment. For more information, please visit: www.cadrenal.com.